Effects of constant and cyclic heat stress on muscle metabolism and meat quality of broiler breast fillet and thigh meat

This study investigated the effects of constant and cyclic heat stress on muscle metabolism and meat quality of broiler breast fillet and thigh meat from 4 to 6 wk of age. Male Arbor Acres (AA) broilers (n = 270, 4 wk old) were raised under different temperature conditions: standard (temperature was 23°C); constant high temperature (temperature was 34°C); and cyclic high temperature (temperature was 36°C from 1000 h to 1600 h and 23°C from 1600 h to 1000 h). On d 42, broilers were stunned and sampled. The results showed that chronic high temperature significantly decreased the proportion of breast muscle and significantly increased the proportion of thigh muscle (P < 0.05). The moisture concentration was significantly higher in the breast muscle of the birds exposed to constant high temperature (P < 0.05), whereas the protein content was significantly lower (P < 0.05) and fat deposition was significantly higher (P < 0.05) in the breast muscle of the birds exposed to constant or diurnal cyclic high temperature than those grown under standard temperature. The breast and thigh muscle of the birds grown under constant high temperature had significantly higher lightness, cook loss, and shear force (P < 0.05) and significantly lower initial pH (pH(i)), ultimate pH (pH(u)), and redness compared with those grown under standard temperature (P < 0.05). The pH(i), pH(u), and redness were significantly lower (P < 0.05) while the lightness and shear force were significantly higher for the breast muscle of the chickens raised under diurnal cyclic high temperature (P < 0.05) than those grown under standard temperature. In contrast, lightness and yellowness of thigh muscle were significantly higher (P < 0.05) in the chickens grown under diurnal cyclic high temperature than under standard temperature. Breast and thigh muscle of broilers exposed to constant high temperature produced higher (P < 0.05) lactic acid and pyruvate kinase activities than those exposed to the standard temperature. These results indicated that chronic heat stress significantly increased lactate production, reduced meat pH value by accelerating meat glycolysis, and eventually reduced meat quality.

Abstract P2-10-15: Evaluation of Prognostic and Predictive Performance of Breast Cancer Index and Its Components in Hormonal Receptor-Positive Breast Cancer Patients: A TransATAC Study

Background: The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial compared the efficacy and safety of 5 years of anastrozole with tamoxifen as adjuvant treatment for postmenopausal women with localized HR+ breast cancer. At a median follow-up of 10 years, a statistically significant improvement with anastrozole vs. tamoxifen for disease-free survival, time to recurrence and time to distant recurrence was observed. The HOXB13:IL17BR gene expression ratio (H/I) quantifies recurrence risk in ER positive (ER+) breast cancer patients and is predictive of benefit from endocrine therapy. Molecular Grade Index (MGI) is a five-gene index that provides quantitative and objective molecular assessment of tumor grade and proliferative status. Breast Cancer Index (BCI) combines H/I and MGI into a continuous risk model that provides a likelihood of distant recurrence in patients treated with endocrine therapy, and efficacy from neoadjuvant chemotherapy. In the current analysis, evaluation of the prognostic and predictive performance of BCI, H/I and MGI in the ATAC study cohort was conducted.

Methods: Under the TransATAC protocol, formalin-fixed, paraffin-embedded (FFPE) blocks of primary tumor were collected from HR+ patients from each monotherapy arm. The current study examined samples collected from the United Kingdom, which constituted 79% of the collection. RNA extracted from 1102 samples from the TransATAC study was amplified, converted to cDNA and subjected to RT-PCR with primers and probes to HOXB13, IL17BR, BUB1A, CENPA, NEK2, RACGAP1 and RRM2. H/I, MGI and BCI were calculated and risk groups were determined using pre-specified cutpoints.

Results: Of 1102 tumor specimens assayed, 29 failed QC criteria, leaving 1073 samples for analysis. Detailed results on the prognostic and predictive performance of BCI, H/I and MGI will be presented. Data on whether BCI and its components provided independent prognostic information in the presence of classical variables, their prognostic value for risk of late recurrence, interaction by treatment arms, and comparative performance vs other models will also be discussed.

Discussion: The ATAC trial has established the long-term efficacy and safety of anastrozole over tamoxifen as initial adjuvant treatment for post-menopausal early stage breast cancer patients. Continued efforts are needed to improve on quantification of residual risk in patients who were treated with endocrine therapy to guide decision-making in selecting additional adjuvant chemotherapy and/or administering extended endocrine treatment. This study will help to establish the strategy to more effectively select patients for adjuvant therapies.

Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-10-15.

Abstract P1-07-13: Prognostic relevance of statistically standardized estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in tamoxifen(TAM)-treated NCIC CTG MA.14 patients

Background: Poor inter-laboratory comparability of common clinically used breast cancer biomarkers led to a proposal of statistical standardization (SS) of laboratory results, similar to bone mineral density (BMD) z-scores. This analysis is the first utilization of SS in a trial where all women received TAM.

Methods: MA.14 allocated 667 postmenopausal women to TAM +/− Octreotide LAR (OCT) based on locally determined ER/PR, without HER2 status. At 9.8 yrs median follow-up, the secondary endpoint of relapse-free survival (RFS) had a non-significant hazard ratio (HR) for TAM-OCT to TAM of 0.87 (95% CI 0.63–1.21; p = 0.40). 299 patients who were representative of MA.14 patients by treatment and stratification factors (exact Fisher p-values=0.19–0.90) had their tumors centrally assessed for ER, PR, and HER2 by RT-PCR. Continuous values were used for SS of each biomarker. Univariate (uni) assessment used similar categorizations as those for BMD, assigning ER/PR/HER2 values by number of standard deviations (SD) about the mean (Group 1, z-score ≥1.0 SD below mean; Group 2, z-score &lt;1.0 SD below mean; Group 3, z-score ≤1.0 SD above mean; Group 4, z-score &gt;1.0 SD above mean). A log-rank statistic was used to test for differences between SS biomarker groups with K-M plots for graphical description. Multivariate (multi) effects of SS biomarkers and baseline patient characteristics on RFS were examined with exploratory (un)stratified Cox step-wise forward regression, adding a factor if likelihood ratio criterion was p ≤ 0.05. Sensitivity analyses used a prior external HER2+ cut-point of ≥1.32 SD.

Results: 292 patient samples passing internal analytical quality control were included in this analysis. Uni analyses indicated SS ER was not associated with RFS (p = 0.31). SS PR had a significant uni effect on RFS [p = 0.03; Group 4 compared to Group 1, HR of 0.33 (95% CI 0.12–0.90); Group 3 compared to Group 1, HR of 0.42 (95% CI 0.21–0.83); and Group 2 compared to Group 1 HR of 0.70 (95%CI 0.36–1.37)]. SS HER2 also had a significant uni effect on RFS [p = 0.004; Group 4 compared to Group 1, HR of 0.90 (95% CI 0.37–2.16)]; Group 3 compared to Group 1, HR of 0.39 (95% CI 0.18–0.84); and, Group 2 compared to Group 1, HR of 0.34 (95% CI 0.16–0.70)]. Multi stratified/unstratified Cox models indicated T1 tumours (p = 0.02/p = 0.0002) and higher SS PR (p = 0.02/0.01) were associated with significantly longer RFS; other unstratified results showed that N-ve patients had better RFS (p &lt; .0001), while local ER/PR status did not impact RFS (p &gt; 0.05). The HER2+ cut-point of ≥1.32 SD indicated directionally worse RFS (uni p-value=0.05; multi p-value=0.06).

Discussion: In MA.14, all women received TAM. Local ER/PR status using categorical or semi-quantitative values did not impact RFS. A statistically standardized approach using continuous centralized ER, PR, HER2 by RT-PCR demonstrated that increasing PR values were associated with better RFS. Evaluation in other trials may provide support for this methodology.

Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-07-13.

Abstract P1-03-03: milk deposition in women's mammary duct has been a potential risk factor of breast tumor

Background: According to the pathology and general resection specimens, so many patients have breast tumors together with deposited milk. Therefore, we performed this retrospective study to determine the distribution and characteristics of breast diseases in women undergoing mammary ductoscopy and explore the clinical values and implications of mammary ductoscopy in the management of the breast diseases.

Materials & Methods: Total of 10,082 women(20,082 breasts) with a mean age of 39.2 years old (ranging from 12 to 84 years old) underwent mammary ductoscopy from 2002 to 2011. We studied NSND in contrast with SND duct, specially focused on the situation of duct with intraductal mass. Comparing with the pathology, we studied the relationship between duct milk deposition and epithelial hyperplasia.

Results: From this study we concluded that duct milk deposition was a common disease in 25–59 years old women, it occupied 42.89% cases of the mammary ductal disease and almost 46% are NSND. The character of deposited milk became solid from liquid with the age growing up. Duct milk deposition 476/1431(33.26%)was mostly associated with intraductal masses(total 1431 cases), followed by duct dilatation 517/1431(36.13%). Pathology of patients diagnosed by FDS for duct milk deposition are epithelial hyperplasia(100%), adenosis(86.5%), chronic inflammation(8.8%), metaplasia(16.9), florid hyperplasia(10.8%), tumor-like hyperplasia (57.2%), intraductal tumor or fibroadenoma (27.8%), dysplasia (3.0%), breast cancer (11.7%).

Abstract OT2-2-03: Dovitinib (TKI258) or placebo in combination with fulvestrant in postmenopausal, endocrine-resistant HER2–/HR+ breast cancer: a phase II study

Background: Overcoming endocrine resistance is a critical goal in the treatment of hormone receptor-positive (HR+) breast cancer. Molecular mechanisms associated with endocrine resistance include adaptive cross-talk between the estrogen receptor and the fibroblast growth factor receptor (FGFR). Up to 8% of HR+/ human epidermal growth factor receptor 2 negative (HER2–) breast cancer patients have amplification of the FGFR1 gene, which is associated with resistance to endocrine therapy. In preclinical models, resistance to endocrine therapy can be overcome via FGFR1 inhibition. Dovitinib is a potent oral inhibitor of receptor tyrosine kinases, including FGFR, vascular endothelial growth factor receptor (VEGFR), and platelet derived growth factor receptor (PDGFR), that demonstrated antitumor activity in heavily pretreated breast cancer patients with FGF-pathway amplification (FGFR1, FGFR2, or ligand FGF3; Andre et al, ASCO 2011). Dovitinib may reverse resistance to endocrine therapy related to FGF-pathway amplification and may also inhibit angiogenesis, which plays an essential role in breast cancer development. Dovitinib is studied here in combination with fulvestrant to determine if it can improve outcomes in postmenopausal patients with endocrine resistant HER2−/HR+ breast cancer.

Methods: This is a multicenter, randomized, double-blind, placebo-controlled, phase II trial that will enroll postmenopausal HER2–/HR+ locally advanced or metastatic breast cancer patients (N ≈ 150) progressing within 12 months of completion of adjuvant endocrine therapy or after ≤ 1 prior endocrine therapy in the advanced setting. Patients prospectively undergo molecular screening to enrich for FGF amplification (FGFR1, FGFR2, or FGF3 amplification by qualitative polymerase chain reaction (qPCR); 45 amplified and 30 nonamplified patients per arm). Patients are randomized 1:1 (stratified by FGF-amplification and presence of visceral disease) to receive fulvestrant intramuscularly (500 mg q4w [with an additional dose 2 weeks after the initial dose]) in combination with oral dovitinib (500 mg, 5 days on/2 days off) or placebo until disease progression, unacceptable toxicity, death or discontinuation due to any reason (eg, withdrawal). Crossover is not permitted. The primary endpoint is progression-free survival, with tumor assessments performed q8w. Secondary endpoints include overall response rate per RECIST v1.1, duration of response, overall survival, Eastern Cooperative Oncology Group performance status and patient-reported outcome scores over time, and safety. Additionally, the pharmacodynamic effect of dovitinib on FGFR-associated angiogenic pathways in tumor specimens and potential predictive biomarkers of response to dovitinib will be explored.

Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr OT2-2-03.

Abstract P4-06-18: Targeting basal-like breast cancer through downstream effectors of oncogene cooperation

Basal-like breast cancer is a highly aggressive and lethal form of cancer, not amenable to treatment by molecularly targeted agents or conventional chemotherapy effective against other forms of breast cancer. Thus, discovery of novel intervention targets regulating tumorigenesis in basal-like breast cancer cells is critical. The success of molecularly targeted therapies against some forms of cancer has led to a search for additional cancer cell-specific targets that will permit effective tumor inhibition with minimal damage to normal cells. These efforts are largely focused on identification of novel oncogenes and tumor suppressors by genome sequencing or synthetic lethalities found via genome-wide RNAi screens. We employ a novel approach to identify cancer cell vulnerabilities among genes disregulated downstream of cooperating oncogenic mutations, which drive malignant transformation in large part through synergistic modulation of non-mutated downstream effector genes, the ‘cooperation response genes’ (CRGs) [McMurray et al., Nature, 19 June 2008]. After assessing how common was CRG disregulation in different epithelial cancers, via comparative genomic analysis of CRG expression patterns in tumor vs. normal tissue, we found that 34 CRGs (∼35%) were significantly disregulated in breast cancer. Because of the need for novel intervention targets in basal-like breast cancer, we focused our functional analysis there. We have tested a subset of CRGs disregulated in breast tumors for their contribution to malignancy in basal-like breast cancer cells, re-setting CRG levels toward normal cell levels by stable cDNA expression or shRNA-mediated knock-down and testing tumor formation capacity of perturbed cells. Our studies reveal that CRGs play an essential role in controlling tumor formation of basal-like breast cancer cells, with significant reductions in tumor volume, and in some cases reduced tumor incidence, upon CRG modulation. Disruption of cell behavior appears to be limited to cancer cells, as non-transformed mammary cells harboring analogous perturbations retain capacity to form acinar structures in 3D culture. Several FDA approved pharmacological agents, identified to reverse the CRG expression pattern, display inhibitory effects on basal-like breast cancer cell lines, with minimal effects on non-transformed cells. CRGs thus represent cancer cell-specific vulnerabilities in basal-like breast cancer, providing novel and unexpected opportunities for intervention against this difficult-to-target disease.

Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-06-18.

Measurements of B(c)+ production and mass with the B(c)+ → J/ψπ+ decay

Measurements of B(c)(+) production and mass are performed with the decay mode B(c)(+)→J/ψπ(+) using 0.37 fb(-1) of data collected in pp collisions at √[s]=7 TeV by the LHCb experiment. The ratio of the production cross section times branching fraction between the B(c)(+)→J/ψπ(+) and the B(+)→J/ψK(+) decays is measured to be (0.68±0.10(stat)±0.03(syst)±0.05(lifetime))% for B(c)(+) and B(+) mesons with transverse momenta p(T)>4 GeV/c and pseudorapidities 2.5<η<4.5. The B(c)(+) mass is directly measured to be 6273.7±1.3(stat)±1.6(syst) MeV/c(2), and the measured mass difference with respect to the B(+) meson is M(B(c)(+))-M(B(+))=994.6±1.3(stat)±0.6(syst) MeV/c(2).

Tunneling-nanotube direction determination in neurons and astrocytes

A tunneling nanotube (TNT) is a newly discovered structure involved in cell-cell communication and is found in various types of cells. Here we identify S100A4 as an extracellular molecule and describe its role in attracting the growth direction of TNTs. Together with its putative receptor, receptor for advanced glycation end product, we demonstrate their involvement in TNT direction guidance. Our results further suggest a mechanism for direction guidance of TNTs. In TNT-initiating cells, p53 activates caspase-3, which leads to S100A4 cleavage and its subsequent decrease in cellular concentration. The decrease in cellular S100A4 induces the formation of a gradient of S100A4, from a low concentration in initiating cells toward a high concentration in target cells. This concentration gradient of S100A4 induces direction guidance for TNTs.

Knock-down of USP22 by small interfering RNA interference inhibits HepG2 cell proliferation and induces cell cycle arrest

The Ubiquitin--specific protease 22 (USP22) is a new putative cancer stem cell marker, which plays a significant role in tumorigenesis and cell--cycle progression. However, little is known about the impact of USP22 knock--down on the growth of human hepatoma cell lines. In this study, elevated expression of USP22 was observed in the human HepG2 hepatic cancer cell line compared to the normal human hepatocyte Chang liver cell line. Subsequently, we used siRNA specifically suppressing expression of USP22 and observed that the knock--down of USP22 could effectively induce cell cycle arrest and inhibit HepG2 cell proliferation. Furthermore, our results showed that USP22 deletion caused down--regulation of cyclin D2 expression and up--regulation of p15 and p21 expression. Collectively, Our findings indicate that USP22 may be responsible for HepG2 cell growth and USP22 regulates the cell cycle via the c--Myc/cyclin D2 pathway and down--regulating p15 and p21 expression in HepG2 cell.

Electroacupuncture alleviates affective pain in an inflammatory pain rat model

Pain has both sensory-discriminative and emotional-affective dimensions. Previous studies demonstrate that electroacupuncture (EA) alleviates the sensory dimension but do not address the affective. An inflammatory pain rat model, produced by a complete Freund adjuvant (CFA) injection into the hind paw, was combined with a conditioned place avoidance (CPA) test to determine whether EA inhibits spontaneous pain-induced affective response and, if so, to study the possibility that rostral anterior cingulate cortex (rACC) opioids underlie this effect. Male Sprague-Dawley rats (250-275 g, Harlan) were used. The rats showed place aversion (i.e. affective pain) by spending less time in a pain-paired compartment after conditioning than during a preconditioning test. Systemic non-analgesic morphine (0.5 and 1.0 mg/kg, i.p.) inhibited the affective reaction, suggesting that the affective dimension is underpinned by mechanisms different from those of the sensory dimension of pain. Morphine at 0.5 and at 1 mg/kg did not induce reward. Rats given EA treatment before pain-paired conditioning at GB 30 showed no aversion to the pain-paired compartment, indicating that EA inhibited the affective dimension. EA treatment did not produce reward or aversive effect. Intra-rACC administration of D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr amide (CTOP), a selective mu opioid receptor antagonist, but not norbinaltorphimine (nor-BNI), a selective kappa opioid receptor antagonist, blocked EA inhibition of the affective dimension. These data demonstrate that EA activates opioid receptors in the rACC to inhibit pain-induced affective responses and that EA may be an effective therapy for both the sensory-discriminative and the affective dimensions of pain.

IL-17 and IFN-γ production in peripheral blood following BCG vaccination and Mycobacterium tuberculosis infection in human

BACKGROUND

During Mycobacterium tuberculosis (Mtb) infection, cells of the immune system rely on cytokines to regulate the activity of other immune and structural cells such as IFN-gamma and IL-4. Recent studies suggest that Th17 cells secreting IL-17 may play a potential role in tuberculosis (TB) development.

AIM

To assess the effect of IL-17 on TB development, we provide a systematic review on the production of IL-17, IFN-gamma and IL-4 in infants or children vaccinated with BCG and in TB patients.

MATERIALS AND METHODS

The literature relevant with IL-17 and IFN-gamma production with or without IL-4 on human TB was retrieved from PubMed, EMBASE, Cochrane Library, BIOSIS Previews and the China Biomedicine Literature Databases (CBM) using the search terms "Interleukin-17 or Th17 cells" and "Tuberculosis". The information of included studies, the production of IL-17 and IFN-gamma responding to antigens in the peripheral blood in vitro, was independently extracted by the first two researchers and subsequently qualitatively analyzed.

RESULTS

Nine studies from a total of 226 retrieved publications met the criteria. These included studies showed that BCG vaccination induced dramatically high level of IL-17 similar to IFN-gamma; The level of IL-17 and IFN-gamma were low while IL-4 was high in patients with active TB; IL-17 and IFN-gamma had a similar trend of increase during the conversion from active to latent TB while IL-4 inclined to decrease in this process.

CONCLUSIONS

IL-17 acts as an effector molecule similar to IFN-gamma after BCG vaccination and Mtb infection to protect human against TB. The current findings do not support IL-17 as an inducer of tissue damage in TB.

Self-assembly of montmorillonite platelets during drying

This work is prompted by the quest for nanocomposites in which ordered, layered reinforcement preforms similar in structure to the arrangements seen in nacre are achieved without complex automated layer-by-layer assembly. Lamellar structures were obtained in montmorillonite films simply by slow drying without the use of additives. Clay alignment was found in films derived from suspensions of less than 0.9 vol%, ranging over a pH range of 2-11, at low drying rates and with both the natural ionic strength of the clay suspension and adjusted ionic strength. The greatest degree of order was found at the unadjusted pH and ionic strength. This method offers a potentially simple way of preparing clay preforms for polymer-clay nanocomposites at a drying rate at or below 23 nm s(-1).

Retrospective analysis of ten cases of congenital sublingual teratoid cyst

AIM

The aims of this study were to perform clinicopathological analyses of teratoid cysts of the floor of the mouth and to assess the possibility of surgical treatment.

MATERIALS AND METHODS

The incidence, manifestations, histogenesis, treatment and prognosis of 10 patients admitted to our department between April 2000 and May 2008 were reviewed.

RESULTS

Teratoid cysts occurred almost exclusively in neonates and children, and appeared as mobile, cystic solid and well-defined lesions. Because of the special location, consequences such as difficulty in feeding, breathing and even impairment in growth and development frequently occur. Results of histological examination indicated that squamous, respiratory and gastrointestinal epithelium composed the basic structure of teratoid cyst. Transonogram, CT and MRI examination were conducted, and complete surgical excision was the only treatment of choice. Usually, immediate treatment is not necessary unless the cyst obstructs the upper airway. There has been no recurrence of the lesion after surgery.

CONCLUSION

Although teratoid cyst of the floor of the mouth is a cystic disease, it affects patients to a great extent because of its special location. Therefore, early and complete excision is mandatory for good prognosis.

A comparison of the clinical characteristics of women with recurrent major depression with and without suicidal symptomatology

BACKGROUND

The relationship between recurrent major depression (MD) in women and suicidality is complex. We investigated the extent to which patients who suffered with various forms of suicidal symptomatology can be distinguished from those subjects without such symptoms.

METHOD

We examined the clinical features of the worst episode in 1970 Han Chinese women with recurrent DSM-IV MD between the ages of 30 and 60 years from across China. Student's t tests, and logistic and multiple logistic regression models were used to determine the association between suicidality and other clinical features of MD.

RESULTS

Suicidal symptomatology is significantly associated with a more severe form of MD, as indexed by both the number of episodes and number of MD symptoms. Patients reporting suicidal thoughts, plans or attempts experienced a significantly greater number of stressful life events. The depressive symptom most strongly associated with lifetime suicide attempt was feelings of worthlessness (odds ratio 4.25, 95% confidence interval 2.9-6.3). Excessive guilt, diminished concentration and impaired decision-making were also significantly associated with a suicide attempt.

CONCLUSIONS

This study contributes to the existing literature on risk factors for suicidal symptomatology in depressed women. Identifying specific depressive symptoms and co-morbid psychiatric disorders may help improve the clinical assessment of suicide risk in depressed patients. These findings could be helpful in identifying those who need more intense treatment strategies in order to prevent suicide.

Preoperative T staging of advanced gastric cancer using double contrast-enhanced ultrasound

PURPOSE

To determine the accuracy of double contrast-enhanced ultrasound (DCEUS), in which intravenous microbubbles are used together with an oral contrast agent, in the preoperative T staging of advanced gastric cancer.

MATERIALS AND METHODS

This prospective, ethics committee-approved study recruited 350 patients who gave informed consent. All had gastric cancer proved by endoscopic biopsy and underwent preoperative ultrasound staging using the TNM classification (UICC 2002). The results of DCEUS were compared with postoperative pathologic findings. The staging accuracy of oral contrast-enhanced ultrasound (OCEUS) and DCEUS were compared to each other. Sensitivity and specificity for assessing serosal involvement by DCEUS were evaluated, and the concordance of this method was analyzed using Kappa statistics.

RESULTS

The accuracies of OCEUS and DCEUS in determining the T stage of advanced gastric cancer were 75.1 % (70.4 % for T2, 79.5 % for T3, 68.1 % for T4) and 87.4 % (83.3 % for T2, 89.7 % for T3, 87.2 % for T4), respectively, and the difference between the two methods was statistically significant (χ2 = 17.364, p< 0.001). The performance of DCEUS for staging lesions in the cardia (69.81 %), fundus (85.71 %) and body (85.56 %) had lower accuracy than that of other parts (93.94 % for antrum; 92.11 % for pylorus). Sensitivity and specificity for assessing serosal involvement by DCEUS were 98.76 % and 83.33 % respectively. The reliability was almost perfect with Kappa values of 0.89 (p< 0.001) for intra-observer and 0.82 (p< 0.001) for inter-observer agreement.

CONCLUSION

DCEUS could be considered as an accurate, non-invasive, and reliable diagnostic method for preoperative staging of advanced gastric cancer.

Cytokines induced by long-term potentiation (LTP) recording: a potential explanation for the lack of correspondence between learning/memory performance and LTP

The relationship between learning/memory performance and long-term potentiation (LTP) induction is ambiguous. Although a large body of data supports a strong correspondence between learning/memory performance and LTP, many studies have also provided evidence to the contrary. In this study, we found that 2-month-old senescence-accelerated mice/prone 8 (SAMP8 mice) displayed both impaired performance in a Morris Water Maze (MWM) and enhanced LTP compared to senescence-accelerated mice/resistance 1 (SAMR1). BALB/c mice challenged with Complete Freund's Adjuvant (CFA) performed better in the shuttle-box test but displayed impaired LTP compared to intact animals. It is interesting that BALB/c mice challenged with Incomplete Freund's Adjuvant (IFA) performed better than intact animals, with no LTP impairment. Cytokine analysis showed no significant differences between the interleukin-6 (IL-6), interleukin-10 (IL-10) or TNF-α content in the intact hippocampal tissues of either the SAMR1 and SAMP8 mice or the immune-challenged BALB/c and intact animals. Further analysis demonstrated that the increase in cytokine content was higher in the hippocampal tissues used for LTP recording in the SAMR1 and CFA-challenged animals compared to the SAMP8 and intact BALB/c mice. A correlation analysis demonstrated that pro-inflammatory cytokines (IL-6 and TNF-α) displayed a negative correlation with LTP, while an anti-inflammatory cytokine (IL-10) displayed a positive correlation with LTP. These results suggest that pro-inflammatory cytokines induced by LTP manipulation in experiments (e.g., via tissue injury caused by electrode insertion) may be one of the factors contributing to the observed lack of correspondence between memory/learning ability and LTP.